Ayse Burus
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ayse Burus has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Basak Celtikci
Hacettepe University, Faculty of Medicine, Department of Biochemistry, Ankara, Türkiye
3 shared publications - Yasemin Aksoy
Department of Medical Biochemistry, Faculty of Medicine, Hacettepe University, Ankara, Turkey
2 shared publications - Hande Canpinar
Department of Basic Oncology, Institute of Cancer Hacettepe University Ankara Turkey
1 shared publication - Hatice Dogan Buzoglu
Professor Dr., Department of Endodontics, Hacettepe University, Faculty of Dentistry, Ankara, Turkey
1 shared publication - Mehmet Ozcan
Zonguldak Bülent Ecevit Üniversitesi
1 shared publication - Mete Ucdal
Hacettepe University Faculty of Medicine
1 shared publication
Latest Publications
- Open Access
- 30 April 2026
- Published by Springer Nature in BMC Oral Health
- Vol. 26 (1)
Clinical and early biochemical responses to botulinum toxin type-A in refractory masticatory myofascial pain: a pilot single-arm study
Masticatory myofascial pain (MMP) is a common subtype of temporomandibular disorders (TMD) characterized by muscle tenderness and pain during jaw function.
- 30 April 2026
- Published by Springer Nature in BMC Oral Health
- Vol. 26 (1)
Open AccessClinical and early biochemical responses to botulinum toxin type-A in refractory masticatory myofascial pain: a pilot single-arm study
Masticatory myofascial pain (MMP) is a common subtype of temporomandibular disorders (TMD) characterized by muscle tenderness and pain during jaw function.
- Open Access
- 27 February 2025
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 398 (8) , 10569-10580
The effect of the combination therapy with chlorophyllin, a glutathione transferase P1-1 inhibitor, and docetaxel on triple-negative breast cancer invasion and metastasis in vivo/in vitro
The expression of glutathione S-transferase P1 (GSTP1) enzyme increases in cancer cells, leading to anticancer drug resistance. The antioxidant chlorophyllin has an inhibitory effect on GSTP1. In this study, we investigated the effect of chlorophyllin and its combined administration with the chemotherapeutic agent docetaxel on metastatic processes. For this purpose, both the 4T1 triple-negative breast cancer cell line and metastatic animal model were used. The MTT, flow cytometry, and wound healing assays were used to investigate cell viability, cell cycle, and cell migration, respectively. Total gelatinase activity, GST activity, and glutathione levels in cell and liver tissue lysates measured by colorimetric methods. Micrometastases were evaluated histochemically in liver tissue sections. As a result, the coadministration of chlorophyllin and docetaxel significantly inhibited cell migration in vitro. There was a significant decrease in the total gelatinase activity in vivo. We found that only combined treatment reduced the micrometastatic lesions in the liver tissues, though this reduction was not statistically significant. In conclusion, the coadministration of chlorophyllin and docetaxel may have a potential role in controlling metastatic processes by suppressing cell migration, gelatinase activity, and micrometastasis formation in triple-negative breast cancers. Graphical Abstract
- 27 February 2025
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 398 (8) , 10569-10580
Open AccessThe effect of the combination therapy with chlorophyllin, a glutathione transferase P1-1 inhibitor, and docetaxel on triple-negative breast cancer invasion and metastasis in vivo/in vitro
The expression of glutathione S-transferase P1 (GSTP1) enzyme increases in cancer cells, leading to anticancer drug resistance. The antioxidant chlorophyllin has an inhibitory effect on GSTP1. In this study, we investigated the effect of chlorophyllin and its combined administration with the chemotherapeutic agent docetaxel on metastatic processes. For this purpose, both the 4T1 triple-negative breast cancer cell line and metastatic animal model were used. The MTT, flow cytometry, and wound healing assays were used to investigate cell viability, cell cycle, and cell migration, respectively. Total gelatinase activity, GST activity, and glutathione levels in cell and liver tissue lysates measured by colorimetric methods. Micrometastases were evaluated histochemically in liver tissue sections. As a result, the coadministration of chlorophyllin and docetaxel significantly inhibited cell migration in vitro. There was a significant decrease in the total gelatinase activity in vivo. We found that only combined treatment reduced the micrometastatic lesions in the liver tissues, though this reduction was not statistically significant. In conclusion, the coadministration of chlorophyllin and docetaxel may have a potential role in controlling metastatic processes by suppressing cell migration, gelatinase activity, and micrometastasis formation in triple-negative breast cancers. Graphical Abstract
- Open Access
- 29 December 2024
- Published by Hacettepe University - Medical School in Acta Medica
- Vol. 55 (4) , 227-246
Genetic heterogeneity and metabolic reprogramming in breast cancer
Breast cancer is the most prevalent cancer and the leading cause of cancer-related mortality among women. Recent breakthroughs in breast cancer therapeutics have significantly enhanced outcomes for hormone receptor-positive and HER2-negative subtypes. However, the emergence of drug resistance, particularly in triple-negative breast cancer, presents a formidable challenge. The intricate interplay of genetic and metabolic diversity within breast cancer cells is pivotal to its development. By reprogramming metabolic pathways, cancer cells can adapt and thrive, meeting the demands of survival, growth, and invasion. These metabolic shifts also play a key role in the development of resistance to conventional therapies. This review explores the genetic and metabolic complexities of breast cancer, emphasizing the diverse subtypes and their unique profiles. We examine how genetic variations and metabolic alterations contribute to breast cancer development and progression, influencing both treatment efficacy and resistance. By integrating insights into the genetic background and metabolic reprogramming of breast cancer subtypes, this review aims to highlight the genetic variations and metabolic alterations that contribute to the pathogenesis of breast cancer, with a vision of advancing more precise and effective targeted therapies as well as discovering of novel diagnostic and prognostic markers.
- 29 December 2024
- Published by Hacettepe University - Medical School in Acta Medica
- Vol. 55 (4) , 227-246
Open AccessGenetic heterogeneity and metabolic reprogramming in breast cancer
Breast cancer is the most prevalent cancer and the leading cause of cancer-related mortality among women. Recent breakthroughs in breast cancer therapeutics have significantly enhanced outcomes for hormone receptor-positive and HER2-negative subtypes. However, the emergence of drug resistance, particularly in triple-negative breast cancer, presents a formidable challenge. The intricate interplay of genetic and metabolic diversity within breast cancer cells is pivotal to its development. By reprogramming metabolic pathways, cancer cells can adapt and thrive, meeting the demands of survival, growth, and invasion. These metabolic shifts also play a key role in the development of resistance to conventional therapies. This review explores the genetic and metabolic complexities of breast cancer, emphasizing the diverse subtypes and their unique profiles. We examine how genetic variations and metabolic alterations contribute to breast cancer development and progression, influencing both treatment efficacy and resistance. By integrating insights into the genetic background and metabolic reprogramming of breast cancer subtypes, this review aims to highlight the genetic variations and metabolic alterations that contribute to the pathogenesis of breast cancer, with a vision of advancing more precise and effective targeted therapies as well as discovering of novel diagnostic and prognostic markers.
- Open Access
- 1 January 2024
- Published by Kare Publishing in Hepatology Forum
- Vol. 5 (3) , 150-160
Cross talk between genetics and biochemistry in the pathogenesis of hepatocellular carcinoma
The liver is a crucial organ in the regulation of metabolism, signaling, and homeostasis. Using recent advanced sequencing technologies, several mutations of genes in major metabolic and signaling pathways have been discovered in the pathogenesis of hepatocellular carcinoma (HCC). These gene signatures alter expression and ultimately affect biochemical pathways by modifying enzyme/protein levels, resulting in numerous clinical outcomes related to HCC. It comes with varying forms of genetic and biochemical alterations, associated with carbohydrate, lipid, nucleic acid, and amino acid metabolism, as well as signaling pathways linked to tumorigenesis. Here, we aim to summarize the main components and mechanisms involved in the progression of HCC with a special focus on the metabolic regulation of key effectors of tumorigenesis, through the crosstalk between genetics and biochemistry. This paper provides an overview of hepatocellular carcinoma, underlying the fundamental effect of gene variations on metabolic and signaling pathways. Since there is still an unmet need for biomarkers and novel therapeutic targets, some of these signature genes or proteins can be used as novel biomarkers for diagnosis, prognosis, and novel potential therapeutic targets for the treatment of HCC
- 1 January 2024
- Published by Kare Publishing in Hepatology Forum
- Vol. 5 (3) , 150-160
Open AccessCross talk between genetics and biochemistry in the pathogenesis of hepatocellular carcinoma
The liver is a crucial organ in the regulation of metabolism, signaling, and homeostasis. Using recent advanced sequencing technologies, several mutations of genes in major metabolic and signaling pathways have been discovered in the pathogenesis of hepatocellular carcinoma (HCC). These gene signatures alter expression and ultimately affect biochemical pathways by modifying enzyme/protein levels, resulting in numerous clinical outcomes related to HCC. It comes with varying forms of genetic and biochemical alterations, associated with carbohydrate, lipid, nucleic acid, and amino acid metabolism, as well as signaling pathways linked to tumorigenesis. Here, we aim to summarize the main components and mechanisms involved in the progression of HCC with a special focus on the metabolic regulation of key effectors of tumorigenesis, through the crosstalk between genetics and biochemistry. This paper provides an overview of hepatocellular carcinoma, underlying the fundamental effect of gene variations on metabolic and signaling pathways. Since there is still an unmet need for biomarkers and novel therapeutic targets, some of these signature genes or proteins can be used as novel biomarkers for diagnosis, prognosis, and novel potential therapeutic targets for the treatment of HCC
- 1 July 2023
- Published by Bentham Science Publishers Ltd. in Current Stem Cell Research & Therapy
- Vol. 18 (5) , 641-652
Stem Cell and Oxidative Stress-Inflammation Cycle
: Under a variety of physical and experimental settings, stem cells are able to self-renew and differentiate into specialized adult cells. MSCs (mesenchymal stromal/stem cells) are multipotent stem cells present in a wide range of fetal, embryonic, and adult tissues. They are the progenitors of a variety of specialized cells and are considered crucial tools in tissue engineering. MSCs, derived from various tissues, including cord blood, placenta, bone marrow, and dental tissues, have been extensively examined in tissue repair, immune modulation, etc. Increasing the vitality of MSCs and restoring cellular mechanisms are important factors in treatment success. : Oxidative stress harms cellular molecules such as DNA, proteins, and lipids due to the overproduction of reactive oxygen species (ROS) and reactive nitrogen species (RNS) in cells and tissues or insufficiency of antioxidant systems that can inactivate them. Oxidative stress has a close link with inflammation as a pathophysiological process. ROS can mediate the expression of proinflammatory genes via intracellular signaling pathways and initiate the chronic inflammatory state. At the same time, inflammatory cells secrete a large number of reactive species that cause increased oxidative stress at sites of inflammation. In inflammatory diseases, the differentiation of stem cells and the regenerative and wound healing process can be affected differently by the increase of oxidative stress. : Recent studies have indicated that dental pulp stem cells (DPSCs), as a resource of adult stem cells, are an attractive option for cell therapy in diseases such as neurological diseases, diabetes, cardiological diseases, etc., as well as its treatment potential in pulp inflammation. The future of oxidative stressinflammation cycle and/or ageing therapies involves the selective elimination of senescent cells, also known as senolysis, which prevents various age-related diseases. Most pathologies are implicated on the effects of ageing without exerting undesirable side effects.
- 1 July 2023
- Published by Bentham Science Publishers Ltd. in Current Stem Cell Research & Therapy
- Vol. 18 (5) , 641-652
Stem Cell and Oxidative Stress-Inflammation Cycle
: Under a variety of physical and experimental settings, stem cells are able to self-renew and differentiate into specialized adult cells. MSCs (mesenchymal stromal/stem cells) are multipotent stem cells present in a wide range of fetal, embryonic, and adult tissues. They are the progenitors of a variety of specialized cells and are considered crucial tools in tissue engineering. MSCs, derived from various tissues, including cord blood, placenta, bone marrow, and dental tissues, have been extensively examined in tissue repair, immune modulation, etc. Increasing the vitality of MSCs and restoring cellular mechanisms are important factors in treatment success. : Oxidative stress harms cellular molecules such as DNA, proteins, and lipids due to the overproduction of reactive oxygen species (ROS) and reactive nitrogen species (RNS) in cells and tissues or insufficiency of antioxidant systems that can inactivate them. Oxidative stress has a close link with inflammation as a pathophysiological process. ROS can mediate the expression of proinflammatory genes via intracellular signaling pathways and initiate the chronic inflammatory state. At the same time, inflammatory cells secrete a large number of reactive species that cause increased oxidative stress at sites of inflammation. In inflammatory diseases, the differentiation of stem cells and the regenerative and wound healing process can be affected differently by the increase of oxidative stress. : Recent studies have indicated that dental pulp stem cells (DPSCs), as a resource of adult stem cells, are an attractive option for cell therapy in diseases such as neurological diseases, diabetes, cardiological diseases, etc., as well as its treatment potential in pulp inflammation. The future of oxidative stressinflammation cycle and/or ageing therapies involves the selective elimination of senescent cells, also known as senolysis, which prevents various age-related diseases. Most pathologies are implicated on the effects of ageing without exerting undesirable side effects.
- Open Access
- 15 August 2021
- Published by Hacettepe University - Medical School in Acta Medica
- Vol. 52 (3) , 171-179
The Inflammatory Processes Driven by Gut Microbiota
Microbiome studies have shown alterations in bacterial communities in the state of many diseases, including inflammatory bowel disease, metabolic disorders, autoimmune diseases, neurodegenerative diseases, and cancer. Chronic inflammation is a common promoter of many of these pathological processes. Shifting in the microbial diversity is also known as dysbiosis. Dysbiosis, increased detrimental bacterial products, decreased favorable microbial metabolites, interrupted tissue barriers, and bacterial translocation cause excessive immune response and inflammation. Several mechanisms play a role to maintain intestinal homeostasis by limiting bacterial translocation from the intestinal lumen into the lamina propria. Among these mechanisms, most importantly, the mucosal barrier that consists of the antimicrobial peptides, mucus, and immunoglobulin A is fundamental to protect epithelial barrier integrity to reduce the excessive immune response. Moreover, recognizing bacteria and metabolites through receptors results in T cell regulation and immune modulation, which is the keystone of the controlled immune response. This review summarizes the anti-inflammatory and pro-inflammatory mechanisms driven by gastrointestinal microbiota, and it also highlights the recent approaches, including epigenetics and precision medicine.
- 15 August 2021
- Published by Hacettepe University - Medical School in Acta Medica
- Vol. 52 (3) , 171-179
Open AccessThe Inflammatory Processes Driven by Gut Microbiota
Microbiome studies have shown alterations in bacterial communities in the state of many diseases, including inflammatory bowel disease, metabolic disorders, autoimmune diseases, neurodegenerative diseases, and cancer. Chronic inflammation is a common promoter of many of these pathological processes. Shifting in the microbial diversity is also known as dysbiosis. Dysbiosis, increased detrimental bacterial products, decreased favorable microbial metabolites, interrupted tissue barriers, and bacterial translocation cause excessive immune response and inflammation. Several mechanisms play a role to maintain intestinal homeostasis by limiting bacterial translocation from the intestinal lumen into the lamina propria. Among these mechanisms, most importantly, the mucosal barrier that consists of the antimicrobial peptides, mucus, and immunoglobulin A is fundamental to protect epithelial barrier integrity to reduce the excessive immune response. Moreover, recognizing bacteria and metabolites through receptors results in T cell regulation and immune modulation, which is the keystone of the controlled immune response. This review summarizes the anti-inflammatory and pro-inflammatory mechanisms driven by gastrointestinal microbiota, and it also highlights the recent approaches, including epigenetics and precision medicine.